In 2022, The Science Advisory Committee (SAC) on Health Products Containing Cannabis published its report. This report did not change the legal status of CBD but outlined some important recommendations, including a safe dosing schedule for CBD and an openness for CBD to be regulated under a framework like the Natural Health Product Regulations.
On March 21, 2024, the Government’s expert panel on cannabis released a final report concluding its legislative review of the Cannabis Act. The report acknowledged that an increased availability of cannabis-based health products, authorized under the existing framework for natural health products (NHPs), would mark an important advancement, providing Canadians with access to legal products that have been reviewed for safety, quality and efficacy.
Current Advocacy Efforts
Regulating CBD under the Natural Health Products Regulations will enhance accessibility to regulated CBD-containing products for Canadians and unlock growth opportunities for the NHP industry.
CHFA joined the Cannabis Health Products Coalition (CHPC) and has been actively engaging with key members of parliament, Health Canada, and other key stakeholders to advance the regulatory landscape for cannabis health products (CHPs). CHFA has met with senior Health Canada executives, including the Director General of the Natural and Non-prescription Health Products Directorate (NNHPD), as well as various other officials, to advocate for the implementation of a risk-based regulatory framework for CHPs.
For a comprehensive understanding of the subject, we encourage you to review the CHFA advocacy letters provided below.